---
title: Overview
description: Explore cutting-edge peptide therapeutics for metabolic disorders, including GLP-1 agonists, dual and triple receptor agonists, and innovative treatments for obesity and diabetes.
position: 1
---

::card-group
  ::card
  ---
  title: Tirzepatide
  to: /research/tirzepatide
  icon: i-mdi-medication
  ---
  A dual GIP/GLP-1 receptor agonist that significantly improves glycemic control and promotes substantial weight loss in patients with type 2 diabetes.
  ::

  ::card
  ---
  title: Retatrutide
  to: /research/etatrutide
  icon: i-mdi-medication
  ---
  An innovative triple-agonist peptide that targets GIP, GLP-1, and glucagon receptors, offering significant weight loss and metabolic benefits for patients with obesity and type 2 diabetes.
  ::

  ::card
  ---
  title: Cagrilintide
  to: /research/cagrilintide
  icon: i-mdi-medication
  ---
  A cutting-edge, long-acting amylin receptor agonist that offers significant weight loss benefits and improved metabolic control for patients with obesity and type 2 diabetes.
  ::
  ::card
  ---
  title: Dosage
  to: /research/dosage
  icon: i-mdi-medication
  ---
  Explore the optimal dosage regimens for our peptide therapeutics, including Tirzepatide, Retatrutide, and Cagrilintide, to maximize efficacy and minimize adverse events.
::
